Such activities are often altered during human cancer development as highlighted by the frequent appearance of p53 missense mutations in its sequence-specific DNA binding domain [10],[11] which can abrogate or alter p53 transactivational activity that result in changes in biological responses, such as the balance between apoptosis and survival in response to DNA damage. Here, TP53 is linked to cancer.